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brain barrier, gastroentericmucosa, and skin dermis. The ability of CPP to act as transmembrane vectors improves
the clinical application of some biomolecules to treat central nervous system diseases, increase oral bioavailabil-
ity, and develop percutaneous-delivery dosage form.
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Intercellular transposition of biomacromolecules is the basis of phys-
iological and pathological processes. Cell-penetrating peptides (CPPs)
act as cargo carriers and constitute a current hotspot in medical re-
search. They are capable of entering the body in a noninvasive manner
and accelerate the absorption of macromolecules via physiological
mechanisms such as energy-dependent endocytosis and energy-
independent direct penetration [1–4] (Fig. 1). Comparedwith some tra-
ditional techniques, such as microinjection and electroporation [5,6],
CPPs do not destroy the integrity of the cell membranes, and are consid-
ered highly efﬁcient and safe, thus, providing new avenues for research
and applications in life sciences.
Through biomaterial modiﬁcation, CPPs can be refolded and assem-
bled with synthetic nanostructures in order to ameliorate the disadvan-
tages owing to nonselectivity, lower delivery efﬁciency, and decreased
susceptibility to degradation [7–9]. CPPs can be also incorporated into
versatile cargo-carrying platforms to create novel drug-delivery sys-
tems that ensures improved coated-drug uptake, as well as their
targeted recognition and controlled release via stimulus-responsive
mechanisms [10,11]. The extensive use of CPPs in drug delivery will
add considerable potency to protein- and nucleic-acid-based drugs
[12–15], thereby increasing the possibility of biomacromolecular
drugs crossing physiological barriers, such as the blood–brain barrier
(BBB), nose mucous membrane, gastrointestinal mucosa, and skin.
2. Cell penetrating peptides (CPPs)
Currently, hundreds of CPPs have been found and used in biomedical
research. CPPs are generally short peptides consisting of b30 amino
acids and are divided into two main types as follows: 1) a polypeptide
motif derived from natural proteins with penetrating functions, and 2)
artiﬁcially designed and synthesized polypeptides, which are further
optimized as molecule-internalizing vectors.
2.1. Natural-protein-derived CPPs
Many natural proteins can cross plasma membranes, including
transactivators of gene transcription [16], DNA−/RNA-binding proteins
[17], antimicrobial peptides [18,19], viral particle envelope proteins [20,
21], plant circular skeletal proteins [22,23] and so on. The shortest
amino acid sequences associated with these proteins and havingFig. 1. Different internalized mechanism of CPPs-cargo. CPPs-cargo are internalized into the
penetration. The endocytosis can be again divided into 4 kinds as follows: macropinocytosi
independent endocytosis; and the direct penetration are also divided into 4 kinds as follows: cpenetration ability are determined to be CPPs, with several of these re-
lated to TAT [24], VP22 [25], Antp [26], gH625 [27,28], etc.
Studies found that CPPs have no cell speciﬁcity, and as the transport
vehicle, can mediate effective internalization of exogenous proteins,
plasmid DNA, antigens, ﬂuorophores, and peptide nucleic acids into
the cytoplasm and cell nucleus [29–33]. Furthermore, they have com-
mon properties, including rapid cell-membrane penetration, high levels
of nuclear accumulation, identical entering efﬁciency between 4 °C and
37 °C, and low sensitivity to inhibitors of clathrin-mediated endocytosis
[34].
2.2. Artiﬁcial CPPs
Some artiﬁcial CPPs have been designed and synthesized based on
the structures of naturally-derived CPPs. These are fabricated via the re-
placement of key amino acids, splicing diverse functional sequences to-
gether, identiﬁcation based on phage display, or screening by using
messenger RNA-display technology [35,36]. These artiﬁcial CPPs are ca-
pable of being optimized for the improvement of their stability in circu-
lating blood, to escape endolysosomal degradation, improve cellular
internalization, and endow pH-responsive capabilities.
2.2.1. Amino acid replacement
There are two main amino acid substitutions. One is arginine accre-
tion, and the other is histidine replacement. Arginine has a strong posi-
tive charge, which acts as a cell-penetrating motif. Their replacement
can promote CPP penetrating capacity, as the number of arginines pres-
ent in a sequence affects internalization efﬁciency. Various arginine-rich
polypeptides, such as HIV-1 Rev34–50, and FHV coat35–49, contain trans-
membrane properties similar to Tat48–60 [37]. Except for the presence of
seven arginine residues, these polypeptides have no other similarities.
Additionally, their internalization efﬁciency is attenuated as the number
of arginine residue decreases, and is nearly lost when the number is b5
[38]. Amino acids of the penetratin protein are substituted for arginine
or lysine, and the uptake efﬁciency has been compared between the
mutant variants. It is found that penetratin-Arg exhibits higher penetra-
tion ability than that of penetratin-Lys [39]. SR9, HR9, and PR9 are also
arginine-replacing CPPs capable of transporting ﬂuorescent protein
into animal, plant, and bacterial cells [40,41]. These have been used to
carry red quantum dots in the development of new types of bioimaging
technologies [42,43], and transport DNA/siRNA into insect cells in order
to improve their transfection efﬁciencies [44].cell by means of the energy-dependent endocytosis or the energy-independent direct
s, clathrin-dependent endocytosis, caveola-mediated endocytosis and caveola/clathrin
arpet, inverted micelle, barrel-stave pore and toroidal pore.
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pacity under physiological conditions (pKa 6.5) and endolysosome-
escape ability (proton-sponge effect). Using histidine to substitute and
modify CPP sequences results in novel pH-responsive CPPs. The mTAT
(C-5H-TAT-5H-C) protein is synthesized by HIV-1 TAT and is covalently
fusedwith ten histidine and two cysteine residues [45]. The histidine re-
mains negatively charged under normal physiological conditions, but
can be exchanged into positive-charge status under acidic conditions
(pH 5–6), which endows TAT with endosomolytic ability. The mTAT/
PEI shows signiﬁcant improvements (up to 5-fold) in the transfection
efﬁciencies of both the cell lines, with little cytotoxicitywhen compared
with that of the four commercial reagents. H(7)K(R(2)) is designed as a
tumor-speciﬁc pH-responsive peptide, which is constructed as a cell-
penetrating motif [(R(2)) with seven histidines] [46]. At ﬁrst, histidines
form hydrophobic attractions, and the –(R(2))moiety can be temporar-
ily blocked onto the core of polymeric micelles. Secondly, the histidines
are ionized, and the hydrophobic interaction is weakened in the acidic
environment of the tumor tissue, followed by the –(R(2)) moiety
being pushed out in order to increase cell internalization.2.2.2. Functional motif chimera
To synthesize new CPPs, the conjugation of diverse functional amino
acid sequences can be done according to electric charge and capacity.
Pep-1 is an amphiphilic tandem peptide 21 amino acids in length and
containing three domains: a hydrophobic tryptophan-rich region, a hy-
drophilic lysine-rich region, and a spacer-linker region for enhancing
stability and ﬂexibility [47]. This peptide can effectively enter HS-68
cells, and is not toxic to NIH-3T3, 293, or Jurkat cells when its concentra-
tion is b100 μM. Pep-1 canmediate the entry of biomacromolecules into
the cells and then be rapidly separated, eliminating the possibility of in-
terfering with the localization and activity of the molecule [48,49]. TheFig. 2. Construction of mRNA display library and outline of screening method forcomplex of Pep-1/cargo can be kept stable in physiological buffer solu-
tions with insensitivity to serum.
Splicing disparate original CPP sequences can also be considered,
allowing fabrication of CPPs with increased penetration capabilities.
Transportan (TP) consists of 12 N-terminal amino acid residues from
galanin and 14 amino acid residues of mastoparan, allowing retention
of the partial capabilities of both galanin and mastoparan, whose inter-
nalization efﬁciency in plant cells is 2–3-fold higher than that of pVEC
[50]. Besides, JB577 is designed as a modular cell penetrating peptide
whichmediates efﬁcient endosomal escape of large protein, dendrimers
and quantumdots (QDs) [51,52]. JB577peptide consists of the sequence
WG·(DapPal)·VKIKK·P9·GG·H6, subdivided into disparate functional
motifs, whose core is (DapPal)·VKIKK. The His6, Pro9, Gly2, Trp and
Poly(L-proline)motifs are deﬁned as the essential components required
for the endosomal escape of JB577.
2.2.3. Screening from peptide libraries
Because some CPPs' internalization is nonselective, and their trans-
duction efﬁciencies are also too low to be used as intracellular carriers
for therapeutic purposes, some unrecorded encoding and special-
function CPPs can be screened and identiﬁed from peptide libraries
building on the phage-display and messenger RNA-display technology.
By fusion to one of the phage surface proteins, about 109 different
peptides can be expressed on the phage surface, and then the desired
peptides can be selected from these display peptides through binding
to a particular molecule. Chen et al. applied Ph.D-C7C, a phage-display
peptide library, onto the abdominal skin of BALB/cA nude mice and re-
covered phage particles from the blood circulation. Recovered phage
was ampliﬁed and used for the next round of in vivo selection. Following
these rounds, TD-1 peptidewas identiﬁed,whichwas capable of perme-
ating the intact skin [53]. Similarly, Whitney et al. used parallel in vivo
and in vitro selection with phage display to identify some novelisolation of tumor-homing CPPs. Reprinted with permission from ref. [56].
Table 1
A new multifunctional drug delivery system based on CPPs integrated with other vectors.
Delivery
carrier
Special vector CPPs Purpose Delivery system Ref
Liposome Cationic liposome gh625, MPS Anti-cancer PEG-gh625-nanoliposome-MTX, MPS-cytC-liposome [57]
[58]
Polymers PEI, PAMAM Tat,
polyArg
Gene therapy Metal NPs@PEI-Tat, Bodipy-PAMAM-Tat-siRNA,
R-PAMAM-PEG-PAMAM-R-DNA
[59]
[60]
[61]
Nanoparticles Nanomicelles, MNPs, nanosilver,
silica nanoparticles, nanogold
Tat,
G3R6Tat,
Tat49–57
Anti-glioma, gene transfer, MRIA,
antimicrobial anti-tumor PTA
therapy
MPEG-PCL-Tat-nanomicelles, PEI-MNPs-Tat-DNA, AgNP-Tat,
DOX-MSNs-Tat (99 m)Tc/(177)Lu-AuNP-Tat-BN, cpHDL-AuNRs,
[62]
[63]
[64]
[65]
[66]
[67]
MRIA, magnetic resonance imaging applications; MNPs, magnetic nanoparticals; PTA, photothermal ablation; MSNs, mesoporous silica nanoparticles.
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mary sequence or target protease [54].
Comparedwith phage display, messenger RNA display technology is
another method for the construction of random peptide libraries [55].
On account of the smaller molecular size of mRNA display-based com-
plex and the larger number of peptides displayed, mRNA display is
more tailored for isolating CPPs. Eisaku et al. applied this technology
to gain ten novel CPPs as tumor lineage-homing CPPs, which could be
possible to target speciﬁc tumor cells. The screening procedure is
shown in Fig. 2. Among them, CPP2 was successfully internalized by pri-
mary colon adenocarcinoma cells, and CPP44 was capable of invading
hepatic tumor cells in vitro, and with speciﬁcity for myelogenous leuke-
mia tumors in vivo [56].
3. Multifunctional drug-delivery systems (MDDSs) based on CPPs
The clinical application of CPPs for drug delivery is impeded due to
their nonselectivity and weak stability. In addition to using modiﬁca-
tion, addition, or replacement of amino acid sequences to enhance
self-integrity, CPPs can also be combined with other drug vectors, thus
integrating with characteristics associated with various drug-
transportation techniques in order to develop novel MDDSs (Table 1).
Through chemical attachment or modiﬁcation of CPPs on the other
drug vectors, such as liposomes, metal nanoparticles, and cation poly-
mers, the MDDS can further increase the drug-loading, and enhance
the biomembrane-crossing rates and the tissue-absorption efﬁciency
of drugs. These activities can also decrease side effects of therapeutic
agent, such as cellular toxicity, immunogenicity, and hemolytic activity,
to strengthen therapeutic effects on diseases associatedwith tumors, in-
ﬂammation, and viral infections.Fig. 3. Pictorial representation of the transport of dual-functionalized (Tf-CPP) liposo3.1. Targeted drug delivery associated with CPPs
The glycosaminoglycans and phospholipids on tumor cell surfaces
are negatively charged, enabling cationic CPPs to preferentially interact
with and enter tumor cells. For example, penetratin can speciﬁcally bind
to the chondroitin sulfate of tumor cellular membranes, increasing the
anticancer properties of CPPs-cargo [68,69].
Due to the different components of the cell membrane between the
tumor and the normal cells, it is possible to alter CPPs to preferentially
target the tumor cells instead of the normal cells. However, this type
of targeting using charged selectivity results in lower afﬁnity and can
impede the application of CPPs in vivo due to the biological milieu con-
taining negatively charged serum proteins capable of attracting cationic
CPPs [70]. Therefore, there is an urgent need to overcome the limitation
of nonselectivity and indiscriminative distribution when CPPs are used
in drug delivery in vivo.
Tumor cells express special receptors and markers, such as transfer-
rin, RGD, Lys(3)-bombesin (BN), andNGR, whichmay constitute appro-
priate targets [71,72]. Incorporatingwith the characteristics of receptor-
speciﬁc binding to a ligand, CPPs with these targets can be developed
into the targeting preparations [73,74], which increases the capability
of the CPP-complexed drug targeting to tumor tissue.
3.1.1. Combining with CPPs for the target drug delivery
Scientists synthesized tandem peptides after forming conjugations
of CPPs with a ligand or antibody. These could be referred to tumor-
homing peptides, endowing the CPPs with speciﬁcity toward tumor tis-
sues [75]. Liu et al. combined R8 with isomers of the Arg-Gly-Asp (RGD)
peptide through an amide linkage to create three kinds of tandem pep-
tides (R8-GRGD). RGD is the ligand of integrinαVβ3 receptor, which canmes across the endothelial cell barrier. Reprinted with permission from ref. [77].
Fig. 5.Design and function of thenanopeptiﬁer. (A)Nanopeptiﬁerwas a ternary fusion of a
therapeutic payload, an ELPBC composed of a hydrophobic and hydrophilic ELP domain,
and a CPP. (B) At “off” state, 37 °C, nanopeptiﬁers were soluble unimers, displaying a
single CPP on their hydrophilic terminus. At “on” state, 42 °C, nanopeptiﬁers self-
assembled into spherical micelles, displaying a high density of CPPs on the micelle
corona. Reprinted with permission from ref. [85].
Fig. 4. Reversible folding and unfolding of GALA peptides are triggered by pH for endosomal escape. Reprinted with permission from ref. [80].
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portation across the BBB when these R8-GRGD-mediated liposomes
are applied to anti-glioma drug delivery in vivo [76].
3.1.2. Synergizing with CPPs for the target drug delivery
The ligand or antibody and CPPs can also be properly dually modi-
ﬁed on the nanostructure surface to allow synergistic effect targeting
tumor delivery. Three kinds of CPPs were applied to form complexes
with the transferrin-liposomes coating the anticancer drug adriamycin.
As a result, the transferrin bound to Tf-receptor, signiﬁcantly increased
the targeting capability of fusion molecules, and CPPs improved inter-
nalization at tumor cell (Fig. 3) [77]. An immune liposome was also de-
signed, whose surface-modiﬁed McAb 2C5 enabled fusion molecules to
be localized at tumor cellular surface-bound nucleosomes,with the syn-
ergistic TAT executing penetration ability [78].
3.2. Controlled and sustained release based on CPPs
The controlled and sustained release of preparations can be devel-
oped depending on the CPPs combiningwith the physiological environ-
ment of tumorigenesis. Some nanoparticle-delivery systems controlled
by the tumor microenvironment have been designed, which display a
response mechanism that enables hidden CPPs to expose themselves
for activation, resulting in the coated drug in complex with the CPP to
exert their effect only under the stimulus of low pH, hyperthermy, or in-
teraction with speciﬁc enzymes in tumor tissue.
3.2.1. Modulating the activity of CPPs with pH-responsive
At pathologic conditions, tumor has a lowered pH microenviron-
ment in contrast with normal tissue. The approach to harness the cellu-
lar uptake of CPPs for tumor internalization by activating CPPs function
in response to this low tumor pH can be designed. Two main ways can
be applied to modulate the activity of CPPs with pH-responsive. One is
using some materials to temporarily shield the CPP ability, and these
materials, such as the enteric polymer [79] and the hydrazone bond
[78], are pH-sensitive which can be the pH-switch to reveal the CPPs.
The other is designing some CPP-self pH-responsive peptides [80,81]
or CPPs modiﬁed with leucine/histidine sequence [82].
Following these ways, Erez et al. engineered the pH-sensitive
PEGylated long-circulating liposomes. The pH-sensitive hydrazone
bond (PEG2K-Hz-PE) and TAT were modiﬁed on the surface of lipo-
somes. At normal pH, TAT was hidden by the long PEG chains. Upon
the exposure to the acidulating environment of solid tumors, the
hydrazone bond could be degraded and consequently TAT moieties
were exposed enabling permeation of Tat carrying adriamycin into
tumor cells [78].
Aside from using the pH-sensitive stealth coating to hide the CPP
ability, GALA, a designed synthetic pH-responsive amphipathic peptide,
is also applied in drug delivery. GALA is an EALA-repetition peptide,
which assumes a random coil or α-helical structure depending on the
pH of the environment (Fig. 4). At pHb6, GALA adoptsα-helical second-
ary structure, which can insert into membranes and cause membraneleakage. At pHN6, its glutamic acid side chains deprotonate and become
negatively charged, and consequently destabilize the helix structure,
which is membrane inactive. This ability of pH-triggered cell-
penetration makes GALA-based delivery an efﬁcient strategy for
endosomal escape and targeting tumor [80].3.2.2. Activating CPPs' function under thermal stimulus
The method of controlling CPPs' activity relying on the thermal fea-
tures of tumor is also used to enhance cellular uptake of drug in the
tumor. For example, CPPs in complex with doxorubicin (CPP-DOX)
was to coat into thermosensitive liposomes (TSLs), which raised the cir-
culation stability of CPP-DOX in the blood, and enabled the CPP to recov-
er its permeability with DOXduring liquid–solid phase transition of the
TSL followed by stimulation of tumor at high temperatures (40 °C to
42 °C) [83]. In addition, a nanopeptiﬁer that ampliﬁed cellular uptake
by modulating the activity of CPPs with thermally toggled self-
assembly of a genetically encoded polypeptide nanoparticle was con-
structed [84,85]. The nanopeptiﬁer could tune the cellular uptake and
activity of anticancer therapeutics by an extrinsic thermal trigger.
When appendedwith a proapoptotic peptide, the nanopeptiﬁer created
Fig. 6. Schematic diagram of ACPP-DOX conjugate for antitumor drug delivery. Reprinted with permission from ref. [86].
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(Fig. 5) [85].3.2.3. Tune the activity of CPPs by enzyme trigger
An activatable cell penetrating peptide (ACPP) that uses a special
control mechanism based on selective and local unleashing of CPP has
been extensively applied to tumor therapy and molecular imaging
probes. The mechanism of controlled release is mainly through appro-
priate design of linker, making ACPPs to direct toward particular en-
zymes, such as matrix metalloproteinases (MMPs) [86], thrombin [87]
and legumain [88].
Shi et al. devised a hairpin shaped molecule consisting of a
polycationic CPP and an inhibitory polyanion connected through a
MMP-speciﬁc substrates. When intact, the polyanion neutralized the
polycation and largely masked the ability of CPP. Cleavage of the linker
enabled dissociation of the inhibitory polyanion from CPP, releasing the
CPP and associated cargo to adhere to and then penetrate into tumor
cells (Fig. 6). This ACPP-DOX systemwas temporarily inactive in humor-
al circulation, but displayed its activity only in tumor tissue overex-
pressing the MMP-2/9 enzyme [86].
Aside from the release of CPPs from polyanion inhibitors, the CPPs'
function can also be activated by the removal of shield coating to reveal
CPPs. Ze et al. designed a drug carrier through the attachment of
substrate of legumain, alanine–alanine-asparagine (AAN), to TAT.
The addition of the AAN moiety to the fourth lysine in the TAT created
a branched peptide moiety, which led to a decrease in theFig. 7. Schematic illustration of pcCPP/NRG-LP.transmembrane penetration capacity of TAT by 72.5%. Legumain efﬁ-
ciently cleaved the AAN from TAT and thereby recovered the ability of
TAT. Doxorubicin carried by the AAN-TAT-liposome led to an increase
in the tumoricidal effect of doxorubicin and a reduction in its systemic
adverse effects [88].3.2.4. Activating CPPs' function in response to extrinsic light trigger
Above experiments controlled the ability of CPP to be activated by
the in vivo tumormicroenvironment. Therewas also amethod involving
near-infrared or ultraviolet light, which illuminated tumors to stimulate
separation of photosensitive groups (PG) from nanoparticle pcCPP/
NGR-LP, thus controlling the release of therapeutic agents at the
tumor site (Fig. 7) [89,90].
These mechanisms of “microenvironment-stimulus-response” con-
trol the CPP permeability in vivo and ex vivo and consequently control
the drug release. They can signiﬁcantly enhance the selective penetra-
tion of CPPs-drug to tumor or tumor microenvironment and decrease
the damage of drug to normal tissues. In addition, they can also improve
the sustainable-cure timewindowof drugs in systemic blood circulation
and decrease the danger of CPP degradation by proteases. So CPPs asso-
ciated with these stimulus-responsive mechanisms can develop the
multifunctional drug delivery platform with controlled and sustained
release.
In summary, the synergistic or combined effects of CPPs with other
delivery techniques can be developed into aMDDS to promote the cura-
tive effects of macromolecular drugs (Fig. 8).Reprinted with permission from ref. [89].
Fig. 8. CPPs incorporating with other vectors develop new multifunctional drug delivery system.
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Studies indicated that various CPPs had different internalizing capac-
ities through the plasma membrane, with some capable of penetrating
biomembranes, such as the BBB, gastrointestinal tract, and skin. This ac-
tivity enables the transport ofmacromolecules into different tissues and
organs, including the brain parenchyma, gastrointestinal circulation,
and hypodermis to display their biological function (Fig. 9).
4.1. Penetrating effect on BBB
The BBB selectively allows solutes to cross the barrier and blocks
harmful materials entering cerebral circulation in order to maintain
the normal physiological state of the central nervous system (CNS)
[91]. However, the BBB also forms an impassable barrier against macro-
molecular drugs designed for CNS-related diseases, restricting their
clinical application. Research and development of suitable methods to
enable delivery of drugs across the BBB are needed [92,93].
The primary defects of pharmacological and physiological methods
for drug delivery include the following: 1) low concentration of drug
permeate into brain parenchyma; 2) destruction of BBB enables entryFig. 9. CPPs-cargo translocate acrof other toxicants into brain tissues, followed by increased infection
probability and tumor migration; 3) increasing liposolubility of the
drugmay decrease its solubility; and 4) CNS damage cannot be repaired
[94].
The application of CPPs for crossing the BBB is a hopeful way to over-
come some of these defects. Differences in the abilities of Tat,
penetratin, and mastoparan transport of anticancer drugs across the
BBBwere observed [77]. Tat loadedwith siRNA against Raf-1 protein ki-
nase and the anticancer drug camptothecin (CPT) was delivered
through the nasal cavity to kill intracerebral malignant glioma cells
and extend the mouse life span (Fig. 10) [62]. Additionally, penetratin
was able to help RGD permeate SH-SY5Y cells in vitro, and penetratin-
RGD successfully crossed the BBB, reaching to the ischemic
hemicerebrum following a peritoneal injection into local ischemic-
reperfusionmice [95]. D-penetratin/L-penetratinwas also able to deliver
insulin into the cerebral cortex, cerebellum, and brain stem by nasal-
cavity administration. The time-effect curves of pharmacokinetics be-
tween intravenous and pernasal delivery were compared and analyzed,
with the result indicating that pernasal administration of CPPs signiﬁ-
cantly decreased the danger caused by drug exposure of whole body
[96].oss different biomembranes.
Fig. 10. Intranasal drug/siRNA co-delivery to the brain with TAT-modiﬁed nanomicelles. Reprinted with permission from ref. [62].
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The mucosa of gastrointestinal tract is a bottleneck for the absorp-
tion of biomacromolecules following oral administration. Polypeptides
and proteins are often delivered intravenously due to their easier dena-
turation in the endogastric acidic environment and degradation by in-
testinal enzymes. Therefore, new effective methods to raise the oral
bioavailability of polypeptides and protein drugs are urgently required
[97].
CPPs can promote the absorption rate of orally administered protein
drugs via intestinal epidermal mucosa, and also be a safer drug-delivery
method.Mice orally administered penetratin and lipopolysaccharide for
seven days, consequentlywhich exhibited the enhanced oral absorption
and the safety absorption by analyzing glutamate pyruvate transami-
nase, glutamate oxalacetate transaminase, and the degree of liver injury
[98]. Additionally, it was proved that Tat and penetratin promoted the
permeation and intake of insulin into the intestinal epidermal mucosa
byusing a Caco-2monolayer cellmodel in vitro [99]. Bymeans of further
decreasing the probability of proteolysis and hepatorenal clearance
rates, CPPs could also be utilized to enhance the penetrating efﬁciency
and absorption rate of biologics into gastrointestinal mucosa in vivo, op-
timizing the absorption, distribution,metabolism, and excretion process
of protein drugs [100].4.3. Penetrating effect on skin
Skin is a natural barrier that protects the body against external inju-
ry. However, macromolecular penetration of the skin is a signiﬁcant
challengewhen it is necessary to treat skin diseases, including psoriasis,
allergic dermatitis, and skin cancer [101]. Some CPPs, such as meganin,
Tat, TD-1, and penetratin,were found tomediate siRNA and protein-like
biologics crossing the corneum to enter subcutaneous tissue, thus in-
creasing the absorption efﬁciency of target cells [102,103]. Among
these CPPs, local administration of TD-1 increased the systematic up-
take quantity of drugs [53], and Tat was able to effectively deliverTable 2
Different administration routes of CPPs-cargo.
Composition Administration routes Efﬁcacy
TAT-siRNA-CPT Intranasal administration Crossing BBB
Penetratin-RGD Intraperitoneal injection Crossing BBB
L-penetratin-Insulin Intranasal administration Crossing BBB
TAT-Insulin Orally administration Crossing gastrointestinal muc
TAT-LPS Orally administration Crossing gastrointestinal muc
SPACE-siRNA Percutaneous administration Crossing skin mucosa
CPT, camptothecin; LPS, lipopolysaccharide; SPACE, skin penetrating and cell entering.gene drugs into epidermal stem cells [59]. In contrast to penetratin
and LMVP, melittin is a cationic antibacterial protein, capable of pene-
trating the abdominal skin corneum to reach the dermis, and also ex-
hibits curative effects on non-melanoma cancer and skin infection
[104]. The SPACE peptide was screened by phage-display technology,
and displayed the ability to carry protein and to penetrate keratinocytes,
ﬁbrocytes, and endothelial cells in vivo. It was also able to transport
siRNA across the skin corneum to downregulate the expression of target
protein [105]. These studies indicated that someCPPs possess the ability
to cross the skin barrier, and have a great potential for development of
new skin-delivery methods for biological medicine.
In brief, with the ability of biomembranes penetration, CPPs can de-
velop various administration routes for protein and nucleic-acid
pharmacon, enhance and improve their clinical application (Table 2).5. Conclusions
CPPs are capable of transporting macromolecules across
biomembranes, enabling their localization to the cytoplasm, cell nucle-
us, and various tissues for execution of their different functions as fol-
lows: crossing the BBB in order to attack CNS diseases; penetrating
intestinal mucosa to raise drug absorption rates and oral bioavailability;
and permeating skin mucosa to develop percutaneous delivery dosages
of protein and nucleic-acid drugs for clinical use. The penetration capac-
ity of CPPs can also be used for studies of the intracellular mechanisms
and functional effects of biomolecules.
Currently, the main limitations in CPPs application are easy to be
cleaved and degraded by plasma proteases, as well as their lack of spec-
iﬁcity, which cause CPPs to losemembrane-permeation ability. Through
the addition or substitution of key amino acids, or functional group con-
nection or modiﬁcation, CPPs can be further remodeled to increase
function, and incorporated into other delivery techniques in order to
exert synergistic or combined inﬂuence. Modiﬁed CPPs can increase
drug permeating efﬁciency, facilitate efﬁcient endosomal escape,
strengthen the stability of fusion molecules in blood, improve tumor-Function Ref
Kill intracerebral malignant glioma [62]
Reach the ischemic hemicerebrum [95]
Decrease the danger caused by drug exposure of whole body [96]
osa Raise the oral bioavailability of insulin [99]
osa Prove the safety of CPPs as oral absorption enhancer [98]
Increase the absorption efﬁciency of drug to subcutaneous tissue [105]
138 D. Zhang et al. / Journal of Controlled Release 229 (2016) 130–139tissue targeting, and endow cargo-controlled release with stimulus-
responsive mechanisms speciﬁc for tumor microenvironments.
With the advance of research and development, more optimized
CPPs will be discovered and constructed. Moreover, the integration of
various advantages with CPPs will create higher effective and conve-
nient multifunctional drug delivery system, which is the crucial to
their further clinical application and promotes new drug research.
References
[1] S.M. Farkhani, A. Valizadeh, H. Karami, S. Mohammadi, N. Sohrabi, F. Badrzadeh,
Cell penetrating peptides: efﬁcient vectors for delivery of nanoparticles,
nanocarriers, therapeutic and diagnostic molecules, Peptides 57 (2014) 78–94.
[2] W.B. Kauffman, T. Fuselier, J. He, W.C. Wimley, Mechanismmatters: a taxonomy of
cell penetrating peptides, Trends Biochem. Sci. 40 (2015) 749–764.
[3] J. Lin, A. Alexander-Katz, Cell membranes open “doors” for cationic nanoparticles/
biomolecules: insights into uptake kinetics, ACS Nano 7 (2013) 10799–10808.
[4] I. Nakase, H. Akita, K. Kogure, A. Graslund, U. Langel, H. Harashima, S. Futaki, Efﬁ-
cient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating
peptides, Acc. Chem. Res. 45 (2012) 1132–1139.
[5] M. Gebbing, T. Bergmann, E. Schulz, A. Ehrhardt, Gene therapeutic approaches to
inhibit hepatitis B virus replication, World J. Hepatol. 7 (2015) 150–164.
[6] S. Trabulo, A.L. Cardoso, A.M. Cardoso, C.M. Morais, A.S. Jurado, M.C. Pedroso de
Lima, Cell-penetrating peptides as nucleic acid delivery systems: from biophysics
to biological applications, Curr. Pharm. Des. 19 (2013) 2895–2923.
[7] M.J. Pina, S.M. Alex, F.J. Arias, M. Santos, J.C. Rodriguez-Cabello, R.M. Ramesan, C.P.
Sharma, Elastin-like recombinamers with acquired functionalities for gene-
delivery applications, J. Biomed. Mater. Res. A 103 (2015) 3166–3178.
[8] J.M. Swiecicki, M. Di Pisa, F. Lippi, S. Chwetzoff, C. Mansuy, G. Trugnan, G.
Chassaing, S. Lavielle, F. Burlina, Unsaturated acyl chains dramatically enhanced
cellular uptake by direct translocation of a minimalist oligo-arginine lipopeptide,
Chem. Commun. (Camb) 51 (2015) 14656–14659.
[9] C. Douat, C. Aisenbrey, S. Antunes, M. Decossas, O. Lambert, B. Bechinger, A. Kichler,
G. Guichard, A cell-penetrating foldamer with a bioreducible linkage for intracellu-
lar delivery of DNA, Angew. Chem. Int. Ed. Eng. 54 (2015) 11133–11137.
[10] Q.Y. Zhang, H.L. Gao, Q. He, Taming cell penetrating peptides: never too old to
teach old dogs new tricks, Mol. Pharm. 12 (2015) 3105–3118.
[11] Y. Yang, Y.F. Yang, X.Y. Xie, X.S. Cai, X.G. Mei, Synergistic targeted delivery of pay-
load into cancer cells using liposomes co-modiﬁed with photolabile-caged cell-
penetrating peptides and targeting ligands, J. Control. Release 213 (2015) E128.
[12] M.D. Barbosa, Immunogenicity of biotherapeutics in the context of developing
biosimilars and biobetters, Drug Discov. Today 16 (2011) 345–353.
[13] A. Patel, K. Cholkar, A.K. Mitra, Recent developments in protein and peptide paren-
teral delivery approaches, Ther. Deliv. 5 (2014) 337–365.
[14] Y. Sun, Y.-H. Hu, Cell-penetrating peptide-mediated subunit vaccine generates a
potent immune response and protection against streptococcus iniae in Japanese
ﬂounder (Paralichthys olivaceus), Vet. Immunol. Immunopathol. 167 (2015)
96–103.
[15] J.D. Ramsey, N.H. Flynn, Cell-penetrating peptides transport therapeutics into cells,
Pharmacol. Ther. 154 (2015) 78–86.
[16] E. Vives, Cellular uptake [correction of utake] of the Tat peptide: an endocytosis
mechanism following ionic interactions, J. Mol. Recognit. 16 (2003) 265–271.
[17] I. Nakase, H. Hirose, G. Tanaka, A. Tadokoro, S. Kobayashi, T. Takeuchi, S. Futaki,
Cell-surface accumulation of ﬂock house virus-derived peptide leads to efﬁcient in-
ternalization via macropinocytosis, Mol. Ther. 17 (2009) 1868–1876.
[18] J.G. Rodriguez Plaza, R. Morales-Nava, C. Diener, G. Schreiber, Z.D. Gonzalez, M.T.
Lara Ortiz, I. Ortega Blake, O. Pantoja, R. Volkmer, E. Klipp, A. Herrmann, G. Del
Rio, Cell penetrating peptides and cationic antibacterial peptides: two sides of
the same coin, J. Biol. Chem. 289 (2014) 14448–14457.
[19] K. Splith, I. Neundorf, Antimicrobial peptides with cell-penetrating peptide proper-
ties and vice versa, Eur. Biophys. J. 40 (2011) 387–397.
[20] X. Yu, Z. Xu, J. Lei, T. Li, Y. Wang, VP22 mediates intercellular trafﬁcking and en-
hances the in vitro antitumor activity of PTEN, Mol. Med. Rep. 12 (2015)
1286–1290.
[21] K. Hew, S.L. Dahlroth, L.X. Pan, T. Cornvik, P. Nordlund, VP22 core domain from
herpes simplex virus 1 reveals a surprising structural conservation in both the
alpha- and gammaherpesvirinae subfamilies, J. Gen. Virol. 96 (2015) 1436–1445.
[22] C. D'Souza, S.T. Henriques, C.K. Wang, D.J. Craik, Structural parameters modulating
the cellular uptake of disulﬁde-rich cyclic cell-penetrating peptides: MCoTI-II and
SFTI-1, Eur. J. Med. Chem. 88 (2014) 10–18.
[23] L. Cascales, S.T. Henriques, M.C. Kerr, Y.H. Huang, M.J. Sweet, N.L. Daly, D.J. Craik,
Identiﬁcation and characterization of a new family of cell-penetrating peptides: cy-
clic cell-penetrating peptides, J. Biol. Chem. 286 (2011) 36932–36943.
[24] A. Fittipaldi, M. Giacca, Transcellular protein transduction using the Tat protein of
HIV-1, Adv. Drug Deliv. Rev. 57 (2005) 597–608.
[25] A. Okada, A. Kodaira, S. Hanyu, S. Izume, K. Ohya, H. Fukushi, Intracellular localiza-
tion of equine herpesvirus type 1 tegument protein VP22, Virus Res. 192 (2014)
103–113.
[26] D. Derossi, G. Chassaing, A. Prochiantz, Trojan peptides: the penetratin system for
intracellular delivery, Trends Cell Biol. 8 (1998) 84–87.
[27] S. Galdiero, A. Falanga, G. Morelli, M. Galdiero, gH625: a milestone in understand-
ing the many roles of membranotropic peptides, Biochim. Biophys. Acta 1848
(2015) 16–25.[28] R. Tarallo, T.P. Carberry, A. Falanga, M. Vitiello, S. Galdiero, M. Galdiero, M. Weck,
Dendrimers functionalized with membrane-interacting peptides for viral inhibi-
tion, Int. J. Nanomedicine 8 (2013) 521–534.
[29] M.P. Schutze-Redelmeier, H. Gournier, F. Garcia-Pons, M. Moussa, A.H. Joliot, M.
Volovitch, A. Prochiantz, F.A. Lemonnier, Introduction of exogenous antigens into
the MHC class I processing and presentation pathway by Drosophila antennapedia
homeodomain primes cytotoxic T cells in vivo, J. Immunol 157 (1996) (1950)
650–655.
[30] J. Ruczynski, P.M. Wierzbicki, M. Kogut-Wierzbicka, P. Mucha, K. Siedlecka-
Kroplewska, P. Rekowski, Cell-penetrating peptides as a promising tool for deliv-
ery of various molecules into the cells, Folia Histochem. Cytobiol. 52 (2014)
257–269.
[31] N.Q. Shi, X.R. Qi, B. Xiang, Y. Zhang, A survey on “Trojan horse” peptides: opportu-
nities, issues and controlled entry to “Troy”, J. Control. Release 194 (2014) 53–70.
[32] M. Wojciechowska, J. Ruczynski, P. Rekowski, M. Alenowicz, P. Mucha, M. Pieszko,
A. Miszka, M. Dobkowski, H. Bluijssen, Synthesis and hybridization studies of a
new CPP-PNA conjugate as a potential therapeutic agent in atherosclerosis treat-
ment, Protein Pept. Lett. 21 (2014) 672–678.
[33] E.J. Sayers, K. Cleal, N.G. Eissa, P. Watson, A.T. Jones, Distal phenylalanine modiﬁca-
tion for enhancing cellular delivery of ﬂuorophores, proteins and quantum dots by
cell penetrating peptides, J. Control. Release 195 (2014) 55–62.
[34] F. Wang, Y. Wang, X. Zhang, W. Zhang, S. Guo, F. Jin, Recent progress of cell-
penetrating peptides as new carriers for intracellular cargo delivery, J. Control. Re-
lease 174 (2014) 126–136.
[35] D.M. Copolovici, K. Langel, E. Eriste, U. Langel, Cell-penetrating peptides: design,
synthesis, and applications, ACS Nano 8 (2014) 1972–1994.
[36] S.R. MacEwan, A. Chilkoti, Harnessing the power of cell-penetrating peptides:
activatable carriers for targeting systemic delivery of cancer therapeutics and im-
aging agents, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5 (2013) 31–48.
[37] S. Futaki, T. Suzuki, W. Ohashi, T. Yagami, S. Tanaka, K. Ueda, Y. Sugiura, Arginine-
rich peptides. An abundant source of membrane-permeable peptides having po-
tential as carriers for intracellular protein delivery, J. Biol. Chem. 276 (2001)
5836–5840.
[38] S. Futaki, Membrane-permeable arginine-rich peptides and the translocation
mechanisms, Adv. Drug Deliv. Rev. 57 (2005) 547–558.
[39] H.L. Amand, K. Fant, B. Norden, E.K. Esbjorner, Stimulated endocytosis in penetratin
uptake: effect of arginine and lysine, Biochem. Biophys. Res. Commun. 371 (2008)
621–625.
[40] Y.H. Wang, C.P. Chen, M.H. Chan, M. Chang, Y.W. Hou, H.H. Chen, H.R. Hsu, K. Liu,
H.J. Lee, Arginine-rich intracellular delivery peptides noncovalently transport pro-
tein into living cells, Biochem. Biophys. Res. Commun. 346 (2006) 758–767.
[41] M. Chang, J.C. Chou, C.P. Chen, B.R. Liu, H.J. Lee, Noncovalent protein transduction
in plant cells by macropinocytosis, New Phytol. 174 (2007) 46–56.
[42] B.R. Liu, H.H. Chen, M.H. Chan, Y.W. Huang, R.S. Aronstam, H.J. Lee, Three arginine-
rich cell-penetrating peptides facilitate cellular internalization of red-emitting
quantum dots, J. Nanosci. Nanotechnol. 15 (2015) 2067–2078.
[43] B.R. Liu, J.F. Li, S.W. Lu, H.J. Leel, Y.W. Huang, K.B. Shannon, R.S. Aronstam, Cellular
internalization of quantum dots noncovalently conjugated with arginine-rich cell-
penetrating peptides, J. Nanosci. Nanotechnol. 10 (2010) 6534–6543.
[44] Y.J. Chen, B.R. Liu, Y.H. Dai, C.Y. Lee, M.H. Chan, H.H. Chen, H.J. Chiang, H.J. Lee, A
gene delivery system for insect cells mediated by arginine-rich cell-penetrating
peptides, Gene 493 (2012) 201–210.
[45] S. Yamano, J. Dai, S. Hanatani, K. Haku, T. Yamanaka, M. Ishioka, T. Takayama, C.
Yuvienco, S. Khapli, A.M. Moursi, J.K. Montclare, Long-term efﬁcient gene delivery
using polyethylenimine with modiﬁed Tat peptide, Biomaterials 35 (2014)
1705–1715.
[46] B.X. Zhao, Y. Zhao, Y. Huang, L.M. Luo, P. Song, X. Wang, S. Chen, K.F. Yu, X. Zhang,
Q. Zhang, The efﬁciency of tumor-speciﬁc pH-responsive peptide-modiﬁed poly-
meric micelles containing paclitaxel, Biomaterials 33 (2012) 2508–2520.
[47] M.C. Morris, J. Depollier, J. Mery, F. Heitz, G. Divita, A peptide carrier for the delivery
of biologically active proteins into mammalian cells, Nat. Biotechnol. 19 (2001)
1173–1176.
[48] M.J. Kim, M. Park, D.W. Kim, M.J. Shin, O. Son, H.S. Jo, H.J. Yeo, S.B. Cho, J.H. Park,
C.H. Lee, D.S. Kim, O.S. Kwon, J. Kim, K.H. Han, J. Park, W.S. Eum, S.Y. Choi, Trans-
duced PEP-1-PON1 proteins regulate microglial activation and dopaminergic neu-
ronal death in a Parkinson's disease model, Biomaterials 64 (2015) 45–56.
[49] Z. Ke, A. Gao, P. Xu, J. Wang, L. Ji, J. Yang, Preconditioning with PEP-1-SOD1 fusion
protein attenuates ischemia/reperfusion-induced ventricular arrhythmia in isolat-
ed rat hearts, Exp. Ther. Med. 10 (2015) 352–356.
[50] A. Chugh, F. Eudes, Cellular uptake of cell-penetrating peptides pVEC and
transportan in plants, J. Pept. Sci. (2008) 477–481.
[51] J.B. Delehanty, C.E. Bradburne, K. Boeneman, K. Susumu, D. Farrell, B.C. Mei, J.B.
Blanco-Canosa, G. Dawson, P.E. Dawson, H. Mattoussi, I.L. Medintz, Delivering
quantum dot-peptide bioconjugates to the cellular cytosol: escaping from the
endolysosomal system, Integr. Biol. (Camb). 2 (2010) 265–277.
[52] K. Boeneman, J.B. Delehanty, J.B. Blanco-Canosa, K. Susumu, M.H. Stewart, E. Oh,
A.L. Huston, G. Dawson, S. Ingale, R. Walters, M. Domowicz, J.R. Deschamps, W.R.
Algar, S. Dimaggio, J. Manono, C.M. Spillmann, D. Thompson, T.L. Jennings, P.E.
Dawson, I.L. Medintz, Selecting improved peptidyl motifs for cytosolic delivery of
disparate protein and nanoparticle materials, ACS Nano 7 (2013) 3778–3796.
[53] Y. Chen, Y. Shen, X. Guo, C. Zhang, W. Yang, M. Ma, S. Liu, M. Zhang, L.P. Wen,
Transdermal protein delivery by a coadministered peptide identiﬁed via phage
display, Nat. Biotechnol. 24 (2006) 455–460.
[54] M. Whitney, J.L. Crisp, E.S. Olson, T.A. Aguilera, L.A. Gross, L.G. Ellies, R.Y. Tsien, Par-
allel in vivo and in vitro selection using phage display identiﬁes protease-
dependent tumor-targeting peptides, J. Biol. Chem. 285 (2010) 22532–22541.
139D. Zhang et al. / Journal of Controlled Release 229 (2016) 130–139[55] K. Kamide, H. Nakakubo, S. Uno, A. Fukamizu, Isolation of novel cell-penetrating
peptides from a random peptide library using in vitro virus and their modiﬁca-
tions, Int. J. Mol. Med. 25 (2010) 41–51.
[56] E. Kondo, K. Saito, Y. Tashiro, K. Kamide, S. Uno, T. Furuya, M. Mashita, K. Nakajima,
T. Tsumuraya, N. Kobayashi, M. Nishibori, M. Tanimoto, M. Matsushita, Tumour
lineage-homing cell-penetrating peptides as anticancer molecular delivery sys-
tems, Nat. Commun. 3 (2012) 951.
[57] E. Perillo, E. Allard-Vannier, A. Falanga, P. Stiuso, M.T. Vitiello, M. Galdiero, S.
Galdiero, I. Chourpa, Quantitative and qualitative effect of gH625 on the
nanoliposome-mediated delivery of mitoxantrone anticancer drug to HeLa cells,
Int. J. Pharm. 488 (2015) 59–66.
[58] S.K. Kim, M.B. Foote, L. Huang, The targeted intracellular delivery of cytochrome C
protein to tumors using lipid-apolipoprotein nanoparticles, Biomaterials 33 (2012)
3959–3966.
[59] L.H. Peng, J. Niu, C.Z. Zhang, W. Yu, J.H. Wu, Y.H. Shan, X.R. Wang, Y.Q. Shen, Z.W.
Mao, W.Q. Liang, J.Q. Gao, TAT conjugated cationic noble metal nanoparticles for
gene delivery to epidermal stem cells, Biomaterials 35 (2014) 5605–5618.
[60] T.I. Kim, J.U. Baek, J.K. Yoon, J.S. Choi, K. Kim, J.S. Park, Synthesis and characteriza-
tion of a novel arginine-grafted dendritic block copolymer for gene delivery and
study of its cellular uptake pathway leading to transfection, Bioconjug. Chem. 18
(2007) 309–317.
[61] H. Kang, R. DeLong, M.H. Fisher, R.L. Juliano, Tat-conjugated PAMAMdendrimers as
delivery agents for antisense and siRNA oligonucleotides, Pharm. Res. 22 (2005)
2099–2106.
[62] T. Kanazawa, K. Morisaki, S. Suzuki, Y. Takashima, Prolongation of life in rats with
malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-
penetrating peptide-modiﬁed micelles, Mol. Pharm. 11 (2014) 1471–1478.
[63] H.P. Song, J.Y. Yang, S.L. Lo, Y. Wang, W.M. Fan, X.S. Tang, J.M. Xue, S. Wang, Gene
transfer using self-assembled ternary complexes of cationic magnetic nanoparti-
cles, plasmid DNA and cell-penetrating Tat peptide, Biomaterials 31 (2010)
769–778.
[64] L. Liu, J. Yang, J. Xie, Z. Luo, J. Jiang, Y.Y. Yang, S. Liu, The potent antimicrobial prop-
erties of cell penetrating peptide-conjugated silver nanoparticles with excellent se-
lectivity for gram-positive bacteria over erythrocytes, Nanoscale 5 (2013)
3834–3840.
[65] L. Pan, J. Liu, Q. He, L. Wang, J. Shi, Overcoming multidrug resistance of cancer cells
by direct intranuclear drug delivery using TAT-conjugatedmesoporous silica nano-
particles, Biomaterials 34 (2013) 2719–2730.
[66] N. Jimenez-Mancilla, G. Ferro-Flores, C. Santos-Cuevas, B. Ocampo-Garcia, M. Luna-
Gutierrez, E. Azorin-Vega, K. Isaac-Olive, M. Camacho-Lopez, E. Torres-Garcia, Mul-
tifunctional targeted therapy system based on (99 m) Tc/(177) Lu-labeled gold
nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate can-
cer cells, J. Label. Compd. Radiopharm. 56 (2013) 663–671.
[67] T. Murakami, H. Nakatsuji, N. Morone, J.E. Heuser, F. Ishidate, M. Hashida, H.
Imahori, Mesoscopic metal nanoparticles doubly functionalized with natural and
engineered lipidic dispersants for therapeutics, ACS Nano 8 (2014) 7370–7376.
[68] S. Liu, H. Yang, L. Wan, J. Cheng, X. Lu, Penetratin-mediated delivery enhances the
antitumor activity of the cationic antimicrobial peptideMagainin II, Cancer Biother.
Radiopharm. 28 (2013) 289–297.
[69] H. Yang, S. Liu, H. Cai, L. Wan, S. Li, Y. Li, J. Cheng, X. Lu, Chondroitin sulfate as a mo-
lecular portal that preferentially mediates the apoptotic killing of tumor cells by
penetratin-directed mitochondria-disrupting peptides, J. Biol. Chem. 285 (2010)
25666–25676.
[70] H. Young Kim, S. Young Yum, G. Jang, D.R. Ahn, Discovery of a non-cationic cell
penetrating peptide derived from membrane-interacting human proteins and its
potential as a protein delivery carrier, Sci. Report. 5 (2015) 11719.
[71] S.M. Sagnella, J.A. McCarroll, M. Kavallaris, Drug delivery: beyond active tumour
targeting, Nanomedicine 10 (2014) 1131–1137.
[72] Y. Kawasaki, T. Akiyama, Tumor microenvironment: promising therapeutic target,
Nihon Rinsho 73 (2015) 1283–1287.
[73] J. Conde, A. Ambrosone, V. Sanz, Y. Hernandez, V. Marchesano, F. Tian, H. Child, C.C.
Berry, M.R. Ibarra, P.V. Baptista, C. Tortiglione, J.M. de la Fuente, Design of multi-
functional gold nanoparticles for in vitro and in vivo gene silencing, ACS Nano 6
(2012) 8316–8324.
[74] C.L. Santos-Cuevas, G. Ferro-Flores, C. Arteaga de Murphy, M. Ramirez Fde, M.A.
Luna-Gutierrez, M. Pedraza-Lopez, R. Garcia-Becerra, D. Ordaz-Rosado, Design,
preparation, in vitro and in vivo evaluation of (99 m)Tc-N2S2-Tat(49-57)-
bombesin: a target-speciﬁc hybrid radiopharmaceutical, Int. J. Pharm. 375 (2009)
75–83.
[75] M. Hyvonen, P. Laakkonen, Identiﬁcation and characterization of homing pep-
tides using in vivo peptide phage display, Methods Mol. Biol. 1324 (2015)
205–222.
[76] Y. Liu, L. Mei, Q. Yu, Q. Zhang, H. Gao, Z. Zhang, Q. He, Integrin alphabeta targeting
activity study of different retro-inverso sequences of RGD and their potentiality in
the designing of tumor targeting peptides, Amino Acids 47 (2015) 2533–2539.
[77] G. Sharma, A. Modgil, T. Zhong, C. Sun, J. Singh, Inﬂuence of short-chain cell-
penetrating peptides on transport of doxorubicin encapsulating receptor-
targeted liposomes across brain endothelial barrier, Pharm. Res. 31 (2014)
1194–1209.[78] E. Koren, A. Apte, A. Jani, V.P. Torchilin, Multifunctional PEGylated 2C5-
immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced
tumor cell internalization and cytotoxicity, J. Control. Release 160 (2012) 264–273.
[79] F. Araujo, N. Shrestha, M.A. Shahbazi, D. Liu, B. Herranz-Blanco, E.M. Makila, J.J.
Salonen, J.T. Hirvonen, P.L. Granja, B. Sarmento, H.A. Santos, Microﬂuidic assembly
of a multifunctional tailorable composite system designed for site speciﬁc com-
bined oral delivery of peptide drugs, ACS Nano 9 (2015) 8291–8302.
[80] D.K. Schach, W. Rock, J. Franz, M. Bonn, S.H. Parekh, T. Weidner, Reversible activa-
tion of a cell-penetrating peptide in a membrane environment, J. Am. Chem. Soc.
137 (2015) 12199–12202.
[81] W. Li, F. Nicol, F.C. Szoka Jr., GALA: a designed synthetic pH-responsive amphipath-
ic peptide with applications in drug and gene delivery, Adv. Drug Deliv. Rev. 56
(2004) 967–985.
[82] J. Regberg, L. Vasconcelos, F. Madani, U. Langel, M. Hallbrink, pH-responsive
PepFect cell-penetrating peptides, Int. J. Pharm. 501 (2016) 32–38.
[83] Y. Yang, Y. Yang, X. Xie, X. Cai, H. Zhang, W. Gong, Z. Wang, X. Mei, PEGylated lipo-
somes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin
conjugate for tumor-speciﬁc therapy, Biomaterials 35 (2014) 4368–4381.
[84] S.R. Macewan, A. Chilkoti, Digital switching of local arginine density in a genetically
encoded self-assembled polypeptide nanoparticle controls cellular uptake, Nano
Lett. 12 (2012) 3322–3328.
[85] S.R. MacEwan, A. Chilkoti, Controlled apoptosis by a thermally toggled nanoscale
ampliﬁer of cellular uptake, Nano Lett. 14 (2014) 2058–2064.
[86] N.Q. Shi, W. Gao, B. Xiang, X.R. Qi, Enhancing cellular uptake of activable cell-
penetrating peptide-doxorubicin conjugate by enzymatic cleavage, Int. J.
Nanomedicine 7 (2012) 1613–1621.
[87] M. Whitney, E.N. Savariar, B. Friedman, R.A. Levin, J.L. Crisp, H.L. Glasgow, R.
Lefkowitz, S.R. Adams, P. Steinbach, N. Nashi, Q.T. Nguyen, R.Y. Tsien, Ratiometric
activatable cell-penetrating peptides provide rapid in vivo readout of thrombin ac-
tivation, Angew. Chem. Int. Ed. Eng. 52 (2013) 325–330.
[88] Z. Liu, M. Xiong, J. Gong, Y. Zhang, N. Bai, Y. Luo, L. Li, Y. Wei, Y. Liu, X. Tan, R. Xiang,
Legumain protease-activated TAT-liposome cargo for targeting tumours and their
microenvironment, Nat. Commun. 5 (2014) 4280.
[89] Y. Yang, Y. Yang, X. Xie, Z. Wang, W. Gong, H. Zhang, Y. Li, F. Yu, Z. Li, X. Mei, Dual-
modiﬁed liposomeswith a two-photon-sensitive cell penetrating peptide and NGR
ligand for siRNA targeting delivery, Biomaterials 48 (2015) 84–96.
[90] W. Lin, X. Xie, Y. Yang, H. Liu, X. Fu, Y. Chen, H. Liu, Y. Yang, Enhanced small inter-
fering RNA delivery into cells by exploiting the additive effect between photo-
sensitive peptides and targeting ligands, J. Pharm. Pharmacol. 67 (2015)
1215–1231.
[91] M. Tajes, E. Ramos-Fernandez, X. Weng-Jiang, M. Bosch-Morato, B. Guivernau, A.
Eraso-Pichot, B. Salvador, X. Fernandez-Busquets, J. Roquer, F.J. Munoz, The
blood–brain barrier: structure, function and therapeutic approaches to cross it,
Mol. Membr. Biol. 31 (2014) 152–167.
[92] K. Goyal, V. Koul, Y. Singh, A. Anand, Targeted drug delivery to central nervous sys-
tem (CNS) for the treatment of neurodegenerative disorders: trends and advances,
Cent. Nerv. Syst. Agents Med. Chem. 14 (2014) 43–59.
[93] S. Martel, Learning from our failures in blood–brain permeability: what can be
done for new drug discovery? Expert Opin. Drug Discov. 10 (2015) 207–211.
[94] R. Gabathuler, Approaches to transport therapeutic drugs across the blood–brain
barrier to treat brain diseases, Neurobiol. Dis. 37 (2010) 48–57.
[95] H. Yang, H. Yang, Y. Lu, S. Ma, Y. Liu, G. Jia, J. Bi, C. Wang, Targeted delivery of ex-
tracellular matrix protected against neurologic defects after focal ischemia reperfu-
sion in rats, J. Stroke Cerebrovasc. Dis. 24 (2015) 154–162.
[96] N. Kamei, M. Takeda-Morishita, Brain delivery of insulin boosted by intranasal co-
administration with cell-penetrating peptides, J. Control. Release 197 (2015)
105–110.
[97] el-S. Khafagy, M. Morishita, Oral biodrug delivery using cell-penetrating peptide,
Adv. Drug Deliv. Rev. 64 (2012) 531–539.
[98] E.J. Nielsen, N. Kamei, M. Takeda-Morishita, Safety of the cell-penetrating peptide
penetratin as an oral absorption enhancer, Biol. Pharm. Bull. 38 (2015) 144–146.
[99] N. Kamei, Y. Onuki, K. Takayama, M. Takeda-Morishita, Mechanistic study of the
uptake/permeation of cell-penetrating peptides across a caco-2 monolayer and
their stimulatory effect on epithelial insulin transport, J. Pharm. Sci. 102 (2013)
3998–4008.
[100] L. Di, Strategic approaches to optimizing peptide ADME properties, AAPS J. 17
(2015) 134–143.
[101] M.R. Prausnitz, R. Langer, Transdermal drug delivery, Nat. Biotechnol. 26 (2008)
1261–1268.
[102] Y.C. Kim, P.J. Ludovice, M.R. Prausnitz, Transdermal delivery enhanced bymagainin
pore-forming peptide, J. Control. Release 122 (2007) 375–383.
[103] R. Sawant, V. Torchilin, Intracellular transduction using cell-penetrating peptides,
Mol. BioSyst. 6 (2010) 628–640.
[104] N. Do, G. Weindl, L. Grohmann, M. Salwiczek, B. Koksch, H.C. Korting, M. Schafer-
Korting, Cationic membrane-active peptides — anticancer and antifungal activity
as well as penetration into human skin, Exp. Dermatol. 23 (2014) 326–331.
[105] T. Hsu, S. Mitragotri, Delivery of siRNA and other macromolecules into skin
and cells using a peptide enhancer, Proc. Natl. Acad. Sci. U. S. A. 108 (2011)
15816–15821.
